Filtros de búsqueda

Lista de obras de

A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis

scientific article published on 08 November 2018

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients

artículo científico publicado en 2017

A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model

artículo científico publicado en 2015

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

artículo científico publicado en 2013

A practical update on the use of bortezomib in the management of multiple myeloma

artículo científico publicado en 2006

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

artículo científico publicado en 2009

A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma

artículo científico publicado en 2003

ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients

artículo científico publicado en 2006

Age and aging in blood disorders: multiple myeloma

artículo científico publicado en 2014

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

artículo científico publicado en 2013

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

An update in treatment options for multiple myeloma in nontransplant eligible patients

artículo científico

Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program

artículo científico publicado en 2010

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

artículo científico publicado en 2008

Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.

artículo científico publicado en 2005

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

artículo científico publicado en 2019

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

artículo científico publicado en 2016

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

artículo científico publicado en 2013

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial

artículo científico publicado en 2012

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study

artículo científico publicado en 2008

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2005

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

artículo científico publicado en 2013

CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.

artículo científico publicado en 2007

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

artículo científico publicado en 2016

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy

artículo científico publicado en 2011

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

artículo científico publicado en 2014

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors

artículo científico publicado en 2014

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

artículo científico publicado en 2008

Chemotherapy-induced peripheral neuropathies in hematological malignancies

artículo científico publicado en 2014

Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain

scholarly article published in Molecular Pain

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

artículo científico publicado en 2014

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

artículo científico publicado en 2008

Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review

artículo científico publicado en 2013

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

artículo científico publicado en 2011

Cost determinants in aggressive non-Hodgkin's lymphoma

artículo científico publicado en 2005

Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology ⬇️

artículo científico publicado el 9 de mayo de 2011

Current multiple myeloma treatment strategies with novel agents: a European perspective

scientific article published on 19 January 2010

Cytarabine dose for acute myeloid leukemia

artículo científico publicado en 2011

Cytokine and viral load kinetics in human herpesvirus 8-associated multicentric Castleman's disease complicated by hemophagocytic lymphohistiocytosis

artículo científico publicado en 2015

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

scholarly article by Andrew Spencer et al published 20 September 2018 in Haematologica

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

artículo científico publicado en 2016

Dealing with neuropathy in plasma-cell dyscrasias

scientific article published on January 2010

Diagnosis and risk stratification in multiple myeloma

artículo científico

Disseminated intravascular coagulation at diagnosis is a strong predictor for both arterial and venous thrombosis in newly diagnosed acute myeloid leukemia

artículo científico publicado en 2016

Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status

artículo científico publicado en 2004

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study

artículo científico publicado en 2012

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

artículo científico publicado en 2008

Economic assessment in the management of non-Hodgkin's lymphoma

artículo científico publicado en 2004

Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.

artículo científico publicado en 2004

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

artículo científico publicado en 2003

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome

artículo científico publicado en 2011

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

artículo científico publicado en 2009

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis

scholarly article by Hedwig M Blommestein et al published May 2019 in Haematologica

Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression

artículo científico publicado en 2004

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

artículo científico publicado en 2016

European Myeloma Network guidelines for the management of multiple myeloma-related complications

artículo científico publicado en 2015

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

European myeloma network: the value of collaborative research

artículo científico publicado en 2005

European perspective on multiple myeloma treatment strategies: update following recent congresses

artículo científico publicado en 2012

Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement

artículo científico publicado en 2014

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativ

artículo científico publicado en 2015

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

artículo científico publicado en 2008

Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis

artículo científico publicado en 2002

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

artículo científico publicado en 2018

Front-line treatment in younger patients with multiple myeloma

artículo científico publicado en 2009

Functional characteristics of photochemically treated platelets

artículo científico publicado en 2004

Future directions in multiple myeloma treatment

artículo científico publicado en 2005

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

artículo científico publicado en 2010

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

artículo científico publicado en 2006

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

artículo científico publicado en 2010

General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma ⬇️

artículo científico publicado el 1 de julio de 2012

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

artículo científico publicado en 2008

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology ⬇️

scholarly article by Molly Went et al published 21 December 2018 in Blood Cancer Journal

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

artículo científico publicado en 2011

Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia

artículo científico publicado en 2005

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma ⬇️

artículo científico publicado en 2016

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

artículo científico publicado en 2015

Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis

artículo científico publicado en 2015

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

artículo científico publicado en 2014

Health‐related quality of life and disease‐specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population‐based study using the PROFILES registry ⬇️

artículo científico publicado el 1 de agosto de 2012

Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma.

artículo científico publicado en 2009

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

artículo científico publicado en 2003

High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

artículo científico publicado en 2012

High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study

artículo científico publicado en 2010

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

scholarly article by Anjan Thakurta et al published 14 March 2019 in Blood

High-dose daunorubicin in older patients with acute myeloid leukemia

artículo científico publicado en 2009

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

artículo científico publicado en 2013

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

artículo científico publicado en 2017

How to manage neutropenia in multiple myeloma

artículo científico

IMWG consensus on maintenance therapy in multiple myeloma

artículo científico publicado en 2012

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

scientific article published in Nature Communications

Immunophenotyping as a guide for targeted therapy ⬇️

artículo científico publicado el 1 de diciembre de 2003

Impact of genes highly correlated with MMSET myeloma on the survival of non-MMSET myeloma patients

artículo científico publicado en 2016

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2009

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-

artículo científico publicado en 2005

Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response

artículo científico publicado en 2005

Innovations in treatment and response evaluation in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

artículo científico publicado en 2016

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

artículo científico publicado en 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International staging system for multiple myeloma

artículo científico publicado en 2005

Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment

artículo científico publicado en 2009

Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials

artículo científico

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2008

Lenalidomide: a new therapy for multiple myeloma

artículo científico publicado en 2008

MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands

artículo científico publicado en 2017

Management of multiple myeloma in the relapsed/refractory patient.

artículo científico publicado en 2017

Management of multiple myeloma with bortezomib: experts review the data and debate the issues

artículo científico publicado en 2006

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

artículo científico publicado en 2010

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

artículo científico publicado en 2016

Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma.

artículo científico publicado en 2009

Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma

artículo científico publicado el 5 de noviembre de 2010

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

artículo científico publicado en 2009

Multiple myeloma

article

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

scientific article published on 26 March 2011

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

artículo científico publicado en 2013

MyelomA Genetics International Consortium

artículo científico

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

artículo científico publicado en 2008

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

artículo científico publicado en 2003

Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value ⬇️

artículo científico publicado el 1 de junio de 2012

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

artículo científico publicado en 2002

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM

scientific article published on 01 May 2003

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

artículo científico publicado en 2008

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

artículo científico publicado en 2011

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

artículo científico publicado en 2016

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

artículo científico publicado en 2011

Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma

artículo científico publicado en 2014

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial

scientific article published on 04 April 2019

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

artículo científico publicado en 2014

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia

artículo científico publicado en 2010

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

artículo científico publicado en 2015

Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.

artículo científico publicado en 2006

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr

artículo científico publicado en 2006

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

artículo científico publicado en 2010

Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.

artículo científico publicado en 2006

Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?

artículo científico publicado en 2014

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib

artículo científico publicado en 2010

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

artículo científico publicado en 2010

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

artículo científico publicado en 2018

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

artículo científico publicado en 2015

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

artículo científico publicado en 2013

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

artículo científico publicado en 2017

Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe

artículo científico publicado en 2018

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

artículo científico publicado en 2016

Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma

artículo científico

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System ⬇️

artículo científico publicado en 2015

Prevalence of potential underlying aetiology of macrocytic anaemia in Dutch general practice

artículo científico publicado en 2016

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

artículo científico publicado en 2013

Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials

artículo científico publicado en 2011

Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens

artículo científico publicado en 2008

Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2007

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

artículo científico publicado en 2007

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

artículo científico publicado en 2011

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

artículo científico publicado en 2015

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

artículo científico publicado en 2010

Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders

artículo científico publicado en 2012

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

scientific article published on 11 February 2008

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

artículo científico publicado en 2014

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

artículo científico publicado en 2009

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Risk and management of thrombosis in multiple myeloma ⬇️

artículo científico publicado el 1 de abril de 2012

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

artículo científico publicado en 2015

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

artículo científico publicado en 2007

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

artículo científico publicado en 2012

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

artículo científico publicado en 2014

Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy

artículo científico publicado en 2005

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone ⬇️

artículo científico publicado el 27 de septiembre de 2012

Structural domains of vault proteins: a role for the coiled coil domain in vault assembly

artículo científico publicado en 2002

Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion

artículo científico publicado en 2004

Survival and years of life lost in different age cohorts of patients with multiple myeloma

artículo científico publicado en 2010

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

artículo científico publicado en 2018

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

artículo científico publicado en 2011

Thalidomide for treatment of multiple myeloma: 10 years later

artículo científico publicado en 2008

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

artículo científico publicado en 2008

The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas

artículo científico publicado en 2011

The genomic sequence of the murine major vault protein and its promoter

artículo científico publicado en 2002

The myeloma stem cell concept, revisited: from phenomenology to operational terms

artículo científico publicado en 2016

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

artículo científico publicado en 2008

The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands

artículo científico

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients

artículo científico publicado en 2003

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

artículo científico publicado en 2005

Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes

artículo científico publicado en 2008

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016

Treatment of relapsed and refractory multiple myeloma

artículo científico publicado en 2016

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

artículo científico publicado en 2010

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

artículo científico publicado en 2010

Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.

artículo científico publicado en 2013

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial

artículo científico publicado en 2006

Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope

artículo científico publicado en 2005

Vaults: a ribonucleoprotein particle involved in drug resistance? ⬇️

artículo científico publicado el 20 de octubre de 2003

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda